Ida Martinelli, Piero Ruggenenti, Irene Cetin, Giorgio Pardi, Annalisa Perna, Patrizia Vergani, Barbara Acaia, Fabio Facchinetti, Giovanni Battista La Sala, Maddalena Bozzo, Stefania Rampello, Luca Marozio, Olimpia Diadei, Giulia Gherardi, Sergio Carminati, Giuseppe Remuzzi, Pier Mannuccio Mannucci
To assess whether antithrombotic prophylaxis with low-molecular-weight heparin effectively prevents recurrence of late pregnancy complications, 135 women with previous history of preeclampsia, hemolytic anemia, elevated liver enzymes and low platelet count syndrome, intrauterine fetal death, fetal growth restriction, or placental abruption who had been referred within the 12th gestational week were randomized to medical surveillance alone (n = 68) or combined to open-label nadroparin (3800 IU daily subcutaneous injections) treatment (n = 67) in the setting of a randomized, parallel-group, superiority trial, run in Italy from April 2007 to April 2010...
April 5, 2012: Blood